ライフサイエンスコーパス: once-daily dosing

1 ed estimated human half-life consistent with once daily dosing.

2 t achieves stable plasma concentrations with once-daily dosing.

3 rol duration of action in vivo, suitable for once-daily dosing.

4 been discovered, with the hopes of achieving once-daily dosing.

5 lease formulation of tacrolimus designed for once-daily dosing.

6 the efficacy and safety of bosutinib 500 mg once-daily dosing.

7 inetic profile of BG9928 was consistent with once-daily dosing.

8 fold drug accumulation at steady-state after once-daily dosing.

9 three-fold drug accumulation after repeated once-daily dosing.

10 e inhibitor with a half-life that allows for once-daily dosing.

11 returned to baseline levels by 24 hours with once-daily dosing.

12 okinetic (PK) profile that was predictive of once-daily dosing.

13 Chronic steroid use usually involves once-daily dosing, although weekly dosing in children ha

14 ose combinations (FDC) with the advantage of once daily dosing and improved tolerability and toxicity

15 ater bioavailability of LCP-Tacro allows for once-daily dosing and similar (AUC) exposure at a dose a

16 s that demonstrated properties indicative of once-daily dosing and superior potency against resistant

17 Ten women were assigned to receive once-daily dosing and ten were assigned to receive twice

18 Given a favorable tolerability profile, once-daily dosing, and evidence of clinically relevant b

19 ll tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial

20 d MK-0752, 21 patients received a continuous once-daily dosing at 450 and 600 mg; 17 were dosed on an

21 tacrolimus monotherapy with consolidation to once daily dosing by 6 months and once every other day d

22 NaC-transgenic mice to greater than 90% with once-daily dosing by inhalation.

23 The improvements in spirometry with once-daily dosing confirm the long duration of action of

24 was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma

25 e of thromboprophylaxis (heparin, enoxaparin once-daily dosing, early ambulation), hospital discharge

26 y reactions, superior resistance profile and once-daily dosing favours abacavir for African children,

27 than in the past, with lower pill burden and once-daily dosing frequency common.

28 bioavailability and prolonged exposures for once-daily dosing, good colonic absorption and a reliabl

29 At month 6, 90.5% of patients receiving once-daily dosing had maintained clinical remission, com

30 At month 12, 85.4% of patients receiving once-daily dosing had maintained clinical remission, com

31 robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model.

32 s of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advan

33 herapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients.

34 half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.

35 cted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol

36 Once-daily dosing of delayed-release mesalamine at doses

37 ety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for us

38 domized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be ef

39 y dosing (P=0.024) and 93.5% for patients on once-daily dosing (P=0.008).

40 n a higher serum hepcidin concentration than once-daily dosing (p=0.013).

41 In six patients, once-daily dosing produced median serum concentrations a

42 of adverse effects or switch to the use of a once-daily dosing regimen due to compliance issues.

43 ort the concentration-dependent activity and once-daily dosing regimen of telavancin.

44 possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile

45 h human immunodeficiency virus (HIV) include once-daily dosing, simplification of co-treatment for tu

46 tion of BCR-ABL signaling activity following once-daily dosing suggested acute, potent inhibition of

47 over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.

48 Unlike once-daily dosing, twice-daily PAS maintained serum conc

49 Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in

50 izophrenia were randomly assigned to receive once-daily dosing with 10 mg of ABT-126, 25 mg of ABT-12

51 Mice received once-daily dosing with amifostine (10-100 mg/kg, intrape

52 his study provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual

53 The PK profile was supportive of once-daily dosing with median peak plasma concentrations